Viromed Medical AG Reports Positive 2025 Financial Outcome

Viromed Medical AG has announced the financial results for 2025, showcasing a substantial revenue increase. Consolidated revenue reached €5.1 million, a notable rise from the previous year's €1.1 million. The company also achieved net income of €0.6 million, reversing the previous year's loss of €3.1 million. Despite revenues not meeting the projected €8-10 million, net income exceeded expectations.

CEO Uwe Perbandt highlights 2025 as a pivotal year with the launch of ViroCAP®. The product, aimed at treating skin infections using cold plasma technology, received positive market feedback. Viromed also made strides with PulmoPlas®, targeting ventilator-associated pneumonia.

Looking forward to 2026, Viromed anticipates growth driven by anticipated approvals of PulmoPlas® and expansion through international partnerships, particularly with the UMECO Group.